Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
Japan Pharmaceutical Association (JPA) Vice President Daiki Watanabe was appointed on July 8 as a healthcare provider representative on the Central Social Insurance Medical Council (Chuikyo), succeeding former JPA Vice President Masahira Mori. In addition to serving on Chuikyo’s general…
To read the full story
REGULATORY
- MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
- JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
July 9, 2026
- Chuikyo OKs Drug Price Survey Plan for FY2027 Off-Year Revision
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…